{"id":61417,"date":"2026-03-26T16:02:31","date_gmt":"2026-03-26T08:02:31","guid":{"rendered":"https:\/\/flcube.com\/?p=61417"},"modified":"2026-03-26T16:02:32","modified_gmt":"2026-03-26T08:02:32","slug":"lees-pharma-wins-nmpa-approval-for-intrarosa-estrogen-free-dhea-pessary-targets-postmenopausal-vulvovaginal-atrophy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61417","title":{"rendered":"Lee’s Pharma Wins NMPA Approval for Intrarosa \u2013 Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy"},"content":{"rendered":"\n

Lee’s Pharmaceutical Holdings Ltd<\/strong> (HKG: 0950<\/a>) announced National Medical Products Administration (NMPA) marketing approval<\/strong> for Intrarosa Pessary<\/strong>, licensed from U.S.-based Cosette Pharmaceuticals<\/strong>. The prasterone (DHEA)-containing steroid<\/strong> becomes the only estrogen-free therapy approved in China<\/strong> for daily topical treatment of moderate to severe vulvar and vaginal atrophy in postmenopausal women<\/strong> (excluding urinary symptoms), addressing an underserved menopausal health market<\/strong> with ~60 million affected women<\/strong> in China.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Marketing authorization (imported drug)<\/td><\/tr>
Product<\/strong><\/td>Intrarosa Pessary (prasterone 6.5mg)<\/td><\/tr>
Licensor<\/strong><\/td>Cosette Pharmaceuticals (U.S.)<\/td><\/tr>
Licensee<\/strong><\/td>Lee’s Pharmaceutical Holdings Ltd (HKG: 0950)<\/td><\/tr>
Indication<\/strong><\/td>Moderate to severe vulvar and vaginal atrophy in postmenopausal women (excluding urinary symptoms)<\/td><\/tr>
Global Approvals<\/strong><\/td>FDA and EMA approved<\/strong> \u2013 only estrogen-free steroid for daily topical use in menopausal dyspareunia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Intrarosa Specification<\/th><\/tr><\/thead>
Active Ingredient<\/strong><\/td>Prasterone (dehydroepiandrosterone [DHEA])<\/strong> \u2013 6.5mg intravaginal pessary<\/td><\/tr>
Mechanism<\/strong><\/td>Inactive endogenous steroid<\/strong> locally converted to androgens and estrogens<\/strong> in vaginal tissue<\/td><\/tr>
Therapeutic Effect<\/strong><\/td>Restores vaginal epithelial integrity<\/strong>, lubrication<\/strong>, and sexual function<\/strong><\/td><\/tr>
Differentiation<\/strong><\/td>Only estrogen-free<\/strong> option (FDA\/EMA approved); avoids systemic estrogen exposure<\/strong> and endometrial stimulation<\/strong> risks<\/td><\/tr>
Dosing<\/strong><\/td>Daily topical administration<\/strong> \u2013 patient-controlled, convenient<\/td><\/tr>
Target Symptom<\/strong><\/td>Dyspareunia<\/strong> (pain during intercourse) \u2013 key patient-reported outcome<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Strategy<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Menopausal Women<\/strong><\/td>~60 million postmenopausal women<\/strong>; 30\u201350% experience vulvovaginal atrophy<\/strong>; <10% receive adequate treatment<\/strong> \u2013 massive unmet need<\/td><\/tr>
Current Standard of Care<\/strong><\/td>Estrogen creams\/tablets<\/strong> (premarin, estradiol) \u2013 effective but systemic absorption concerns<\/strong>, endometrial monitoring required<\/strong>, breast cancer risk stigma<\/strong><\/td><\/tr>
Intrarosa Differentiation<\/strong><\/td>Estrogen-free<\/strong> = no endometrial stimulation<\/strong>, no black-box warning<\/strong>, breast cancer survivor eligible<\/strong> \u2013 addresses key patient\/physician barriers<\/td><\/tr>
Lee’s Pharma Positioning<\/strong><\/td>Women’s health franchise expansion<\/strong> beyond existing gynecology portfolio; first-mover advantage<\/strong> in DHEA category<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Expected RMB 8,000\u201312,000 annual therapy cost<\/strong> \u2013 premium to generic estrogen but justified by safety profile and convenience<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n